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Abstract:
Voriconazole is a broad-spectrum triazole antifungal agent which has 
emerged as the preferred treatment of invasive aspergillosis in both 
children (≥ 2 years of age) and adults (1, 2). 
Increased voriconazole exposure has been associated with improved 
treatment outcome in adults, with suggested provisional cut-off points 
for voriconazole trough plasma concentrations (Cmin) of 1-6 mg/L (3-6). 
An exposure-response relationship was also established for pediatric 
patients, in which a voriconazole Cmin > 1 mg/L was associated with 
improved outcomes (7-11). Based on the relationship between 
voriconazole exposure and efficacy and the high inter- and intra-patient 
variability in pediatric patients (12-15), the importance of voriconazole 
therapeutic drug monitoring (TDM) in pediatric patients has been 
acknowledged (1, 2, 16, 17). Although TDM-based dose adjustments are 
performed to optimize plasma concentrations, it remains unclear if these 
dose adaptations in pediatric patients correspond with target attainment. 
We conducted a retrospective analysis in a cohort of pediatric oncology 
patients (both leukemia as well as lymphoma) with difficult to manage 
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voriconazole concentrations and assessed the result of TDM-based dose 
adaptations on target attainment.
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34 Abstract (243/250 words)
35
36 Voriconazole is the mainstay of treatment for invasive aspergillosis in immunocompromised pediatric 
37 patients. Although Therapeutic Drug Monitoring (TDM) of voriconazole is recommended, it remains 
38 unknown if TDM-based dose adaptations result in target attainment. 
39 Patients < 19 years from two pediatric hematologic-oncology wards were retrospectively identified 
40 based on unexplained high voriconazole trough concentrations (Cmin >6mg/L). Patient demographics, 
41 clinical characteristics, treatment, voriconazole dosing information, voriconazole Cmin before and 
42 after adjustment based on TDM were obtained. 
43  Twenty-one patients, median (range) age 7.0 (1.2-18.5) years, were identified in two centres. First 
44 Cmin (3.1mg/L [0.1-13.5]) was obtained after 3 days (1-27) of treatment. The median of all Cmin (n=485, 
45 median 11 per patient) was 2.16mg/L (0.0 (undetectable)–28.0), with 24.1% of Cmin <1mg/L, 48.9% 1-
46 4mg/L, 9.3% 4-6mg/L and 17.7% >6mg/L. Intrapatient variability was large (94.1% for IV, 88.5% for 
47 PO). Dose increases at Cmin <1 mg/L resulted in an increased Cmin in 76.4%, with 60% between 1-4 
48 mg/L. Dose decreases at Cmin >6 mg/L resulted in a decreased Cmin in 80%, with 51% between 1-4 
49 mg/L. Overall in 45% of the cases (33 out of 55 and 12 out of 45) therapeutic targets were attained 
50 after dose adjustment. 
51 Fifty-five percent of initial Cmin was outside the therapeutic target of 1-4mg/L, with multiple dose 
52 adaptations required to achieve therapeutic concentrations. Only 60% and 51% of dose adaptations 
53 following sub- and supra-therapeutic Cmin, respectively, did result in target attainment. Intensive and 
54 continuous TDM of voriconazole is a prerequisite for ensuring adequate exposure in pediatric 
55 patients.
56
57
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58 Introduction
59
60 Voriconazole is a broad-spectrum triazole antifungal agent which has emerged as the preferred 
61 treatment of invasive aspergillosis in both children (≥ 2 years of age) and adults (1, 2).
62 Increased voriconazole exposure has been associated with improved treatment outcome in adults, 
63 with suggested provisional cut-off points for voriconazole trough plasma concentrations (Cmin) of 1-6 
64 mg/L (3-6). An exposure-response relationship was also established for pediatric patients, in which a 
65 voriconazole Cmin > 1 mg/L was associated with improved outcomes (7-11). Based on the relationship 
66 between voriconazole exposure and efficacy and the high inter- and intra-patient variability in 
67 pediatric patients (12-15), the importance of voriconazole therapeutic drug monitoring (TDM) in 
68 pediatric patients has been acknowledged (1, 2, 16, 17). Although TDM-based dose adjustments are 
69 performed to optimize plasma concentrations, it remains unclear if these dose adaptations in 
70 pediatric patients correspond with target attainment. 
71 We conducted a retrospective analysis in a cohort of pediatric oncology patients (both leukemia as 
72 well as lymphoma) with difficult to manage voriconazole concentrations and assessed the result of 
73 TDM-based dose adaptations on target attainment.
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75 Materials and Methods
76
77 Study design and patients
78 This retrospective analysis was carried out in the pediatric hematology-oncology wards of two 
79 university hospitals in the Netherlands (Radboud university medical centre, Nijmegen and Sophia 
80 Children’s Hospital, Erasmus Medical Center, Rotterdam). From August 2007–May 2014, the results 
81 from routinely performed TDM of voriconazole in both hospitalized and ambulant pediatric patients 
82 were evaluated. Patients < 19 years who received voriconazole orally (PO) or intravenously (IV) were 
83 included if more than one voriconazole Cmin was determined, of which at least one concentration was 
84 >6 mg/L during treatment. Due to the retrospective nature of the study, written informed consent 
85 was deemed not necessary. 
86
87 Data collection
88 Data was collected from the patients’ medical records and included patient demographics (e.g. age, 
89 gender, body weight), voriconazole treatment data (e.g. route of administration, treatment duration, 
90 total daily dose, dose adjustments) and TDM data (e.g. plasma trough concentrations [Cmin], number 
91 of samples per patient, number of sub- and supra-therapeutic Cmin). Concomitant medications with or 
92 without a known or suspected interaction with voriconazole exposure  were reported. 
93
94 Voriconazole dosing and dose adjustments
95 Initial dosing and administration of voriconazole was according to the Summary of Product 
96 Characteristics (SmPC) of voriconazole, but could be increased or decreased based on clinical 
97 indications and TDM results. End of treatment was defined by successful clinical response, or by 
98 discontinuation due to a lack of clinical response, or adverse events. Consistent with institution 
99 guidelines during the study period, adequate voriconazole exposure was defined as Cmin between 1-4 
100 mg/L. If the patient showed no signs of hepatotoxicity (i.e. liver function tests no more than three 
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101 times the upper limit of normal), Cmin up to 6 mg/L were accepted. The 4 mg/L target concentration to 
102 prevent hepatotoxicity has been established in Asian patients particularly(18, 19). In Caucasion 
103 people this relation has not been established with a clear cut-off value. Rather an increase in drugs 
104 concentration, results in an increased chance of encountering hepatotoxicity(20). In case of 
105 sanctuary infection sites or disseminated disease, the lower threshold was set to 2 mg/L (i.e. 2-4 
106 mg/L or 2-6 mg/L). Target concentrations remain subject to debate but our target concentrations are 
107 in line with the recently published ESCMID guideline(2) and the ECIL guideline [available online via 
108 www.ecil-leukaemia.com]
109 In case of a sub- or supra-therapeutic voriconazole Cmin (< 1 or > 6 mg/L), dose adjustments, assuming 
110 near-linear pharmacokinetics in children (14), to reach adequate Cmin were subsequently made. A 
111 follow-up sample within 1 week was recommended. Dosing frequency was initially two times daily, 
112 but could be increased to three times daily in an attempt to reach adequate voriconazole exposure.
113
114
115 Therapeutic Drug Monitoring
116 TDM was performed as standard of care, but frequency of sampling was dependent on individual 
117 decisions made for each patient. First TDM sample was recommended at steady state concentrations 
118 of the drug, which is at least two days after initiation of voriconazole therapy or following dose 
119 adaptations. Only blood samples withdrawn within a 1 hour period prior to the next dose were 
120 included in the analysis to ascertain a trough concentration. Decisions on dose adaptations were 
121 made by experts in the field with knowledge on PK of voriconazole taking in mind the clinical 
122 condition of the patient. 
123
124 Analytical assay
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125 Voriconazole plasma concentrations were measured twice weekly using an in-house, validated ultra-
126 performance liquid chromatography (HPLC) method with either a fluorescence or MSMS detection 
127 method (Waters). 
128
129 Data analysis
130 A Spearman rank-order correlation was run to determine the relationship between voriconazole dose 
131 and Cmin using SPSS 20.0 (SPSS inc., IL, USA). A p-value of <0.05 was considered statistically significant. 
132 Intra-patient variability of voriconazole Cmin was analyzed in patients who had at least three 
133 voriconazole Cmin at similar doses and formulations. 
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135 RESULTS
136
137 Patients
138 Twenty-one patients (8 male, 13 female) were eligible for analysis. Median (range) age at first dose 
139 was 7.0 years (1.2–18.5 years), of which 3 patients (14.3%) were <2 years, 11 (52.4%) between 2 and 
140 12 years, and 7 (33.3%) between 12 and 19 years. Median (range) weight and BMI were 21.9 kg (9.5–
141 65) and 17.7 kg/m2 (14–25.4), respectively (Table 1). 
142
143 Voriconazole therapy
144 Patients received voriconazole therapy for a median (range) of 118 days (17–866; Table 1). The 
145 median total daily dose per kg (range) was 23.1 mg/kg (6.1–109.6). Initial voriconazole administration 
146 was IV in 15 (71.4%) and PO in 6 (28.6%) of patients. Five patients received voriconazole orally only, 2 
147 only IV, and 14 received a combination of both. In four patients voriconazole was given TID at some 
148 time as part of their management strategy for a median (range) of 60 days (6–397) with a median 
149 total daily dose of 34.4 mg/kg (13.6–109.6). Median intra-individual variability of voriconazole dose 
150 was 94.1% during IV therapy (dose range: 12.2–16.0 mg/kg/day) and 88.5% during PO therapy (dose 
151 range: 10.5–44.1 mg/kg/day). 
152
153 Therapeutic drug monitoring – initial Cmin
154 The first measurement of voriconazole Cmin was performed at a median (range) of 3 days (1–27) after 
155 start of treatment, with a median (IQR) Cmin of 3.1 mg/L (1.34-7.0; Table 1). Upon first measurement, 
156 11 out of 21 (52.4%) patients reached a Cmin between 1-6 mg/L (7 of these patients received 
157 voriconazole IV, 4 PO). Of the remaining 10 patients who had a voriconazole concentration <1 mg/L 
158 or >6 mg/L at first measurement, 5 out of 9 patients (55.5%) required only 1 dose adaptation to 
159 achieve a Cmin between 1-6 mg/L. Target concentrations in these 9 patients were attained after a 
160 median (range) of 15 days (8-123). One patient was unable to achieve target values during the entire 
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161 length of voriconazole therapy despite TDM-based dose adaptations. After the first suboptimal Cmin, 
162 TDM-based dose adaptations were performed within a median of 2 days. A very weak positive 
163 correlation between voriconazole dose and initial Cmin was calculated, which was not statistically 
164 significant (r2=0.05, p=0.82). 
165
166 Therapeutic drug monitoring – all Cmin
167 In total, 485 samples were obtained with a median (range) concentration of 2.16 mg/L (undetectable 
168 -28; Table 1). Four concentrations (0.8%) were reported as below the lower limit of quantification. A 
169 median (range) of 11 samples (2-109) were drawn per patient, of which 117 (24.1%) were <1 mg/L, 
170 237 (48.9%) between 1-4 mg/L, 45 (9.3%) between 4-6 mg/L and 86 (17.7%) >6 mg/L. An overview of 
171 all Cmin per patient is shown in Figure 1. There was no significant correlation between voriconazole 
172 dose and all Cmin, (rs (485)=0.02, p=0.59). A Cmin <1 mg/L was most frequently encountered in patients 
173 >12 years receiving voriconazole IV, whereas patients 2-12 years suffered most frequently from Cmin 
174 >6 mg/L (Figure 2).
175
176 Voriconazole dose adaptations
177 A total of 108 dose increases and 135 dose decreases were made, of which 50.9% when Cmin < 1, 
178 and 33.3% Cmin > 6 (see table 1). Out of a 117 cases with a Cmin <1mg/L prompted a dose increase in 
179 47.0% (n=55) of occurrences, which resulted in an increased Cmin at follow-up sampling in 76.4% 
180 (n=42) of cases. In 60% (n=33) of dose increases following a concentration of <1 mg/L, this led to a 
181 therapeutic Cmin between 1–4 mg/L (median 1.7 mg/L). In these 33 cases, the total daily dose was 
182 increased from a median of 18.3 mg/kg/day to 22.7 mg/kg/day (24.0%). 
183 Out of 86 cases with a Cmin of >6 mg/L (median 8.29 mg/L) this prompted a dose decrease in 52.3% 
184 (n=45) of cases, of which 80.0% (n=36) resulted in a subsequent lower Cmin at follow-up sampling. 
185 These dose decreases resulted in a Cmin of <6mg/L in 51.1% (n=23) of cases and even led to 
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186 concentrations between 1-4 mg/L (median 2.3 mg/L) in 26.7% (n=12). In these 12 cases, the total 
187 daily dose was decreased from a median of 23.5 mg/kg/day to 16.8 mg/kg/day (39.9%). 
188
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190 Discussion
191
192 Here, we present our experience with voriconazole TDM in a cohort of 21 pediatric patients with 
193 difficult to control voriconazole Cmin, characterized by at least one Cmin >6 mg/L, enabling us to assess 
194 the result of TDM-based dose adaptations on voriconazole target attainment. 
195 Overall, 18.5 % of all doses adjustments made, based on TDM, resulted in target concentrations (1-4 
196 mg/L). The vast majority (95.2%) of the patients in our study were able to achieve at least one 
197 therapeutic concentration (1-4 mg/L) after TDM-based dose adjustments. This is in a similar range of 
198 the reported value of 80% in a study from Bartelink et al., although voriconazole target values of 1-5 
199 mg/L were used in this study (21). 
200 Of the total number of 485 voriconazole Cmin, 24.1% was <1 mg/L, which is correlated with increased 
201 likelihood of treatment failure in children (7-9). In case of such a subtherapeutic Cmin, voriconazole 
202 dose was increased in 47.0% of cases. Accordingly, 60% of dose increases resulted in the desired 
203 therapeutic Cmin of 1-4 mg/L, with a median dose increase from 18.3 mg/kg/day to 22.7 mg/kg/day. 
204 Previous studies have reported that dose adjustments to median doses of 20–40 mg/kg/day were 
205 required to obtain therapeutic plasma concentrations of >1 mg/L (9, 10, 22). In addition, 17.7% of the 
206 total number of voriconazole Cminwere >6 mg/L, which is regarded as a cut-off concentration for 
207 hepatotoxicity in adults (23), although no clear correlation is seen in pediatric patients (7, 24, 25) . At 
208 these supratherapeutic concentrations, voriconazole dose was lowered in 52.3% of cases, resulting in 
209 a Cmin between the target range of 1-4 mg/L in 26.7% of cases (decreasing the median dose from 23.5 
210 mg/kg/day to 16.8 mg/kg/day). 
211 Age is one of the most important factors influencing voriconazole plasma exposure, as voriconazole 
212 clearance has been shown to be much higher in children under the age of 12, and oral bioavailability 
213 of voriconazole is lower in children (65%), compared to adults (96%) (14, 26). As a result, several studies 
214 reported similar voriconazole exposure in children (<12 years) compared to adults with IV doses of 7-
215 9 mg/kg BID (13, 14, 26). This prompted higher dosing regimens in children compared to adults. Although 
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216 voriconazole has been reported to display near-linear pharmacokinetics in children receiving multiple 
217 doses of 3 mg/kg and 4 mg/kg BID IV(15) (i.e. doses that have been found effective in clinical trials 
218 with adults), increasing evidence suggests saturated (non-linear) pharmacokinetic behavior is 
219 observed in children receiving doses higher than 7 mg/kg BID. We found no predictable relationship 
220 between dose and Cmin (Figure 1,2) and it remains unclear from current literature if such a 
221 relationship exists. Given the high maintenance doses in our study (median 23.1 mg/kg/day), this 
222 could explain the absence of a dose/concentration relationship. Another explanation could be found 
223 in the high intra-subject variability in voriconazole Cmin both after IV and PO dosing (figure 1), which is 
224 consistent with other pediatric studies (12-14, 26).
225
226 Due to the retrospective nature of this study, laboratory data on the majority of our patients was 
227 limited and often obtained only on the day of voriconazole TDM. In addition, markers for hepatic 
228 function were not always investigated in parallel. It was therefore not possible to draw any 
229 conclusions on the yet unclear relationship between voriconazole Cmin and hepatotoxicity in pediatric 
230 patients. Because the focus of our study on the relationship between dose adjustments and target 
231 attainment, we did not monitor for voriconazole-related adverse events (e.g. neurological adverse 
232 events, phototoxic skin reactions and potentially proarrhythmic conditions) in relation to dose or 
233 exposure.
234
235 Despite rapid dose adaptations after the first subtherapeutic Cmin in our study (median of 2 days), a 
236 median of 15 days were required to obtain an adequate Cmin, increasing the risk of inadequately 
237 treated fungal infections and unfavourable outcome. Of all dose adaptations following both sub –and 
238 supratherapeutic Cmin, only 45% resulted in a therapeutic Cmin between 1-4 mg/L at the following 
239 concentration measurement. If we would stretch the therapeutic targets to 1-6 mg/L (assuming all 
240 Cmin between 4-6 mg/L were acceptable based on adequate liver function tests), 56% of dose 
241 adaptations would result in target attainment.
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242
243 Dose adaptations were done by experts with expertise in the field of antifungal pharmacology but 
244 without a nomogram. For purposes of personalized dosing, there is an urgent need to implement 
245 advanced pharmacometric models with "clinician-proof" software, that can take into account all 
246 important determinants for treatment response. Nowadays model-informed precision dosing (MIPD) 
247 can be deployed as a technique to forecast dosing in the individual. Programs such as InsightRx, 
248 DoseMe and Best Dose fulfil this need and are being tested in the clinic. To take advantage of this 
249 approach, solid pharmacokinetic models must be available to be used in MIPD. Here we can still gain 
250 knowledge for this specific drug and the current population as the unexplained inter-individual 
251 variability in published models remains very large. Before implementation in routine patient 
252 management these models must be prospectively validated to demonstrate its value. In addition the 
253 software must comply to relevant legislation (for instance CE label in Europe) when deployed outside 
254 of a research scope. Nevertheless this is the way forward taking advantage of a platform for 
255 individualized treatment with visual feedback. 
256
257 Given the difficulty of target attainment despite dose adaptations, together with the prior observed 
258 relationship between voriconazole exposure and efficacy and adverse events and the large inter -and 
259 intrapatient variability in children, this study underscores the indispensable need for voriconazole 
260 TDM in severely immunocompromised pediatric patients early i  the course of treatment with 
261 multiple follow-up samples during therapy when aiming to optimize treatment outcomes.
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263 Table 1. Baseline characteristics (n=21).
264
Demographics
Gender
Male (n [%]) 8 (38.1)
Female (n [%]) 13 (61.9)
Median age at first VCZa dose (yrs [range]) 7.0 (1.2 – 18.5)
Age class (yrs)
0 – <2 (n [%]) 3 (14.3)
2 – <12 (n [%]) 11 (52.4)
12 – 18 (n [%]) 7 (33.3)
Race
Caucasian (n [%]) 18 (85.7)
Negroid (n [%]) 2 (9.5)
Asian (n [%]) 1 (4.8)
Median weight (kg [range]) 21.9 (9.5 – 65)
Median BMI (kg/m2 [range]) 17.7 (14 – 25.4)
Voriconazole therapy
Median days of VCZa therapy (n [range]) 118 (17-866)
Intravenous administrations (%) 12.5
Oral administrations (%) 87.5
Median total daily dose (mg [range]) 400 (120-2400)
Median total daily dose per kg (mg/kg [range]) 23.1 (6.1 – 109.6)
Patients on temporarily TIDb dosing (n [%]) 4 (19)
Median days of TIDb dosing (n range)
Median total daily dose during TID dosing (mg/kg [range])
60 (6 – 397)
34.4 (13.6 – 109.6)
TID dosing administrations (% of total) 11.1
Therapeutic drug monitoring
Median days until first measurement of VCZa Cminc (n [range]) 3 (0 – 27)
Median plasma concentration of first Cminc (mg/L [IQRd]) 3.1 (1.34 – 7.0)
Initial Cmin adequate (% of all patients)e 11 (52.4)
Intravenous administration (%) 7 (63.6)
Oral administration (%) 4 (36.4)
Initial Cmin below therapeutic range (% of all patients) 4 (19)
Intravenous administration (%) 3 (75)
Oral administration (%) 1 (25)
Initial Cmin above therapeutic range (% of all patients) 6 (28.6)
Intravenous administration (%) 4 (66.7)
Oral administration (%) 2 (33.3)
Total Cmin 485
<1 mg/L (n [%]) 117 (24.1)
1 – 4 mg/L (n [%]) 237 (48.9)
4 – 6 mg/L (n [%]) 45 (9.3)
>6 mg/L (n [%]) 86 (17.7)
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Median concentration of all Cmin (mg/L; range) 2.16 (0 – 28.0)
Dose adaptations
Dose adaptations (n [%]) 243 (50.1)
Dose increases (total)
Dose increase at Cmin <1 mg/L (n [%])
Resulted in increase in Cmin
Resulted in Cmin 1 – 4 mg/L
108
55 (47)
42 (76.4)
33 (60)
Dose decrease (total)
Dose decrease at Cmin >6 mg/L
Resulted in decrease in Cmin
135
45 (33.3)
36 (80.0)
Resulted in Cmin <6 mg/L 23 (51.1)
Resulted in Cmin 1 – 4 mg/L 12 (26.7)
265
266 aVCZ = voriconazole, bTID = three times per day, c Cmin = trough concentration, dIQR = Interquartile range,  eAdequate 
267 therapeutic range of voriconazole Cmin is considered to be between 1 and 4 mg/L (1-6 if adequate liver function tests). 
268 Subtherapeutic Cmin at <1 mg/L, supratherapeutic Cmin at >6 mg/L.
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270 Figure 1. Overview of all voriconazole trough concentrations at varying doses (n=485) in 21 patients
271
272
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274 Figure 2. Voriconazole Cmin distribution (%) per formulation per age group
275
276 Cmin: trough concentration. IV: intravenous. PO: Oral.
277
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34 Abstract (243/250 words)
35
36 Voriconazole is the mainstay of treatment for invasive aspergillosis in immunocompromised pediatric 
37 patients. Although Therapeutic Drug Monitoring (TDM) of voriconazole is recommended, it remains 
38 unknown if TDM-based dose adaptations result in target attainment. 
39 Patients < 19 years from two pediatric hematologic-oncology wards were retrospectively identified 
40 based on unexplained high voriconazole trough concentrations (Cmin >6mg/L). Patient demographics, 
41 clinical characteristics, treatment, voriconazole dosing information, voriconazole Cmin before and 
42 after adjustment based on TDM were obtained. 
43  Twenty-one patients, median (range) age 7.0 (1.2-18.5) years, were identified in two centres. First 
44 Cmin (3.1mg/L [0.1-13.5]) was obtained after 3 days (1-27) of treatment. The median of all Cmin (n=485, 
45 median 11 per patient) was 2.16mg/L (0.0 (undetectable)–28.0), with 24.1% of Cmin <1mg/L, 48.9% 1-
46 4mg/L, 9.3% 4-6mg/L and 17.7% >6mg/L. Intrapatient variability was large (94.1% for IV, 88.5% for 
47 PO). Dose increases at Cmin <1 mg/L resulted in an increased Cmin in 76.4%, with 60% between 1-4 
48 mg/L. Dose decreases at Cmin >6 mg/L resulted in a decreased Cmin in 80%, with 51% between 1-4 
49 mg/L. Overall in 45% of the cases (33 out of 55 and 12 out of 45) therapeutic targets were attained 
50 after dose adjustment. 
51 Fifty-five percent of initial Cmin was outside the therapeutic target of 1-4mg/L, with multiple dose 
52 adaptations required to achieve therapeutic concentrations. Only 60% and 51% of dose adaptations 
53 following sub- and supra-therapeutic Cmin, respectively, did result in target attainment. Intensive and 
54 continuous TDM of voriconazole is a prerequisite for ensuring adequate exposure in pediatric 
55 patients.
56
57
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58 Introduction
59
60 Voriconazole is a broad-spectrum triazole antifungal agent which has emerged as the preferred 
61 treatment of invasive aspergillosis in both children (≥ 2 years of age) and adults (1, 2).
62 Increased voriconazole exposure has been associated with improved treatment outcome in adults, 
63 with suggested provisional cut-off points for voriconazole trough plasma concentrations (Cmin) of 1-6 
64 mg/L (3-6). An exposure-response relationship was also established for pediatric patients, in which a 
65 voriconazole Cmin > 1 mg/L was associated with improved outcomes (7-11). Based on the relationship 
66 between voriconazole exposure and efficacy and the high inter- and intra-patient variability in 
67 pediatric patients (12-15), the importance of voriconazole therapeutic drug monitoring (TDM) in 
68 pediatric patients has been acknowledged (1, 2, 16, 17). Although TDM-based dose adjustments are 
69 performed to optimize plasma concentrations, it remains unclear if these dose adaptations in 
70 pediatric patients correspond with target attainment. 
71 We conducted a retrospective analysis in a cohort of pediatric oncology patients (both leukemia as 
72 well as lymphoma) with difficult to manage voriconazole concentrations and assessed the result of 
73 TDM-based dose adaptations on target attainment.
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75 Materials and Methods
76
77 Study design and patients
78 This retrospective analysis was carried out in the pediatric hematology-oncology wards of two 
79 university hospitals in the Netherlands (Radboud university medical centre, Nijmegen and Sophia 
80 Children’s Hospital, Erasmus Medical Center, Rotterdam). From August 2007–May 2014, the results 
81 from routinely performed TDM of voriconazole in both hospitalized and ambulant pediatric patients 
82 were evaluated. Patients < 19 years who received voriconazole orally (PO) or intravenously (IV) were 
83 included if more than one voriconazole Cmin was determined, of which at least one concentration was 
84 >6 mg/L during treatment. Due to the retrospective nature of the study, written informed consent 
85 was deemed not necessary. 
86
87 Data collection
88 Data was collected from the patients’ medical records and included patient demographics (e.g. age, 
89 gender, body weight), voriconazole treatment data (e.g. route of administration, treatment duration, 
90 total daily dose, dose adjustments) and TDM data (e.g. plasma trough concentrations [Cmin], number 
91 of samples per patient, number of sub- and supra-therapeutic Cmin). Concomitant medications with or 
92 without a known or suspected interaction with voriconazole exposure  were reported. 
93
94 Voriconazole dosing and dose adjustments
95 Initial dosing and administration of voriconazole was according to the Summary of Product 
96 Characteristics (SmPC) of voriconazole, but could be increased or decreased based on clinical 
97 indications and TDM results. End of treatment was defined by successful clinical response, or by 
98 discontinuation due to a lack of clinical response, or adverse events. Consistent with institution 
99 guidelines during the study period, adequate voriconazole exposure was defined as Cmin between 1-4 
100 mg/L. If the patient showed no signs of hepatotoxicity (i.e. liver function tests no more than three 
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101 times the upper limit of normal), Cmin up to 6 mg/L were accepted. The 4 mg/L target concentration to 
102 prevent hepatotoxicity has been established in Asian patients particularly(18, 19). In Caucasion 
103 people this relation has not been established with a clear cut-off value. Rather an increase in drugs 
104 concentration, results in an increased chance of encountering hepatotoxicity(20). In case of 
105 sanctuary infection sites or disseminated disease, the lower threshold was set to 2 mg/L (i.e. 2-4 
106 mg/L or 2-6 mg/L). Target concentrations remain subject to debate but our target concentrations are 
107 in line with the recently published ESCMID guideline(2) and the ECIL guideline [available online via 
108 www.ecil-leukaemia.com]
109 In case of a sub- or supra-therapeutic voriconazole Cmin (< 1 or > 6 mg/L), dose adjustments, assuming 
110 near-linear pharmacokinetics in children (14), to reach adequate Cmin were subsequently made. A 
111 follow-up sample within 1 week was recommended. Dosing frequency was initially two times daily, 
112 but could be increased to three times daily in an attempt to reach adequate voriconazole exposure.
113
114
115 Therapeutic Drug Monitoring
116 TDM was performed as standard of care, but frequency of sampling was dependent on individual 
117 decisions made for each patient. First TDM sample was recommended at steady state concentrations 
118 of the drug, which is at least two days after initiation of voriconazole therapy or following dose 
119 adaptations. Only blood samples withdrawn within a 1 hour period prior to the next dose were 
120 included in the analysis to ascertain a trough concentration. Decisions on dose adaptations were 
121 made by experts in the field with knowledge on PK of voriconazole taking in mind the clinical 
122 condition of the patient. 
123
124 Analytical assay
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125 Voriconazole plasma concentrations were measured twice weekly using an in-house, validated ultra-
126 performance liquid chromatography (HPLC) method with either a fluorescence or MSMS detection 
127 method (Waters). 
128
129 Data analysis
130 A Spearman rank-order correlation was run to determine the relationship between voriconazole dose 
131 and Cmin using SPSS 20.0 (SPSS inc., IL, USA). A p-value of <0.05 was considered statistically significant. 
132 Intra-patient variability of voriconazole Cmin was analyzed in patients who had at least three 
133 voriconazole Cmin at similar doses and formulations. 
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135 RESULTS
136
137 Patients
138 Twenty-one patients (8 male, 13 female) were eligible for analysis. Median (range) age at first dose 
139 was 7.0 years (1.2–18.5 years), of which 3 patients (14.3%) were <2 years, 11 (52.4%) between 2 and 
140 12 years, and 7 (33.3%) between 12 and 19 years. Median (range) weight and BMI were 21.9 kg (9.5–
141 65) and 17.7 kg/m2 (14–25.4), respectively (Table 1). 
142
143 Voriconazole therapy
144 Patients received voriconazole therapy for a median (range) of 118 days (17–866; Table 1). The 
145 median total daily dose per kg (range) was 23.1 mg/kg (6.1–109.6). Initial voriconazole administration 
146 was IV in 15 (71.4%) and PO in 6 (28.6%) of patients. Five patients received voriconazole orally only, 2 
147 only IV, and 14 received a combination of both. In four patients voriconazole was given TID at some 
148 time as part of their management strategy for a median (range) of 60 days (6–397) with a median 
149 total daily dose of 34.4 mg/kg (13.6–109.6). Median intra-individual variability of voriconazole dose 
150 was 94.1% during IV therapy (dose range: 12.2–16.0 mg/kg/day) and 88.5% during PO therapy (dose 
151 range: 10.5–44.1 mg/kg/day). 
152
153 Therapeutic drug monitoring – initial Cmin
154 The first measurement of voriconazole Cmin was performed at a median (range) of 3 days (1–27) after 
155 start of treatment, with a median (IQR) Cmin of 3.1 mg/L (1.34-7.0; Table 1). Upon first measurement, 
156 11 out of 21 (52.4%) patients reached a Cmin between 1-6 mg/L (7 of these patients received 
157 voriconazole IV, 4 PO). Of the remaining 10 patients who had a voriconazole concentration <1 mg/L 
158 or >6 mg/L at first measurement, 5 out of 9 patients (55.5%) required only 1 dose adaptation to 
159 achieve a Cmin between 1-6 mg/L. Target concentrations in these 9 patients were attained after a 
160 median (range) of 15 days (8-123). One patient was unable to achieve target values during the entire 
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161 length of voriconazole therapy despite TDM-based dose adaptations. After the first suboptimal Cmin, 
162 TDM-based dose adaptations were performed within a median of 2 days. A very weak positive 
163 correlation between voriconazole dose and initial Cmin was calculated, which was not statistically 
164 significant (r2=0.05, p=0.82). 
165
166 Therapeutic drug monitoring – all Cmin
167 In total, 485 samples were obtained with a median (range) concentration of 2.16 mg/L (undetectable 
168 -28; Table 1). Four concentrations (0.8%) were reported as below the lower limit of quantification. A 
169 median (range) of 11 samples (2-109) were drawn per patient, of which 117 (24.1%) were <1 mg/L, 
170 237 (48.9%) between 1-4 mg/L, 45 (9.3%) between 4-6 mg/L and 86 (17.7%) >6 mg/L. An overview of 
171 all Cmin per patient is shown in Figure 1. There was no significant correlation between voriconazole 
172 dose and all Cmin, (rs (485)=0.02, p=0.59). A Cmin <1 mg/L was most frequently encountered in patients 
173 >12 years receiving voriconazole IV, whereas patients 2-12 years suffered most frequently from Cmin 
174 >6 mg/L (Figure 2).
175
176 Voriconazole dose adaptations
177 A total of 108 dose increases and 135 dose decreases were made, of which 50.9% when Cmin < 1, 
178 and 33.3% Cmin > 6 (see table 1). Out of a 117 cases with a Cmin <1mg/L prompted a dose increase in 
179 47.0% (n=55) of occurrences, which resulted in an increased Cmin at follow-up sampling in 76.4% 
180 (n=42) of cases. In 60% (n=33) of dose increases following a concentration of <1 mg/L, this led to a 
181 therapeutic Cmin between 1–4 mg/L (median 1.7 mg/L). In these 33 cases, the total daily dose was 
182 increased from a median of 18.3 mg/kg/day to 22.7 mg/kg/day (24.0%). 
183 Out of 86 cases with a Cmin of >6 mg/L (median 8.29 mg/L) this prompted a dose decrease in 52.3% 
184 (n=45) of cases, of which 80.0% (n=36) resulted in a subsequent lower Cmin at follow-up sampling. 
185 These dose decreases resulted in a Cmin of <6mg/L in 51.1% (n=23) of cases and even led to 
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186 concentrations between 1-4 mg/L (median 2.3 mg/L) in 26.7% (n=12). In these 12 cases, the total 
187 daily dose was decreased from a median of 23.5 mg/kg/day to 16.8 mg/kg/day (39.9%). 
188
Page 32 of 42
http://mc.manuscriptcentral.com/tmmy
Medical Mycology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
190 Discussion
191
192 Here, we present our experience with voriconazole TDM in a cohort of 21 pediatric patients with 
193 difficult to control voriconazole Cmin, characterized by at least one Cmin >6 mg/L, enabling us to assess 
194 the result of TDM-based dose adaptations on voriconazole target attainment. 
195 Overall, 18.5 % of all doses adjustments made, based on TDM, resulted in target concentrations (1-4 
196 mg/L). The vast majority (95.2%) of the patients in our study were able to achieve at least one 
197 therapeutic concentration (1-4 mg/L) after TDM-based dose adjustments. This is in a similar range of 
198 the reported value of 80% in a study from Bartelink et al., although voriconazole target values of 1-5 
199 mg/L were used in this study (21). 
200 Of the total number of 485 voriconazole Cmin, 24.1% was <1 mg/L, which is correlated with increased 
201 likelihood of treatment failure in children (7-9). In case of such a subtherapeutic Cmin, voriconazole 
202 dose was increased in 47.0% of cases. Accordingly, 60% of dose increases resulted in the desired 
203 therapeutic Cmin of 1-4 mg/L, with a median dose increase from 18.3 mg/kg/day to 22.7 mg/kg/day. 
204 Previous studies have reported that dose adjustments to median doses of 20–40 mg/kg/day were 
205 required to obtain therapeutic plasma concentrations of >1 mg/L (9, 10, 22). In addition, 17.7% of the 
206 total number of voriconazole Cminwere >6 mg/L, which is regarded as a cut-off concentration for 
207 hepatotoxicity in adults (23), although no clear correlation is seen in pediatric patients (7, 24, 25) . At 
208 these supratherapeutic concentrations, voriconazole dose was lowered in 52.3% of cases, resulting in 
209 a Cmin between the target range of 1-4 mg/L in 26.7% of cases (decreasing the median dose from 23.5 
210 mg/kg/day to 16.8 mg/kg/day). 
211 Age is one of the most important factors influencing voriconazole plasma exposure, as voriconazole 
212 clearance has been shown to be much higher in children under the age of 12, and oral bioavailability 
213 of voriconazole is lower in children (65%), compared to adults (96%) (14, 26). As a result, several studies 
214 reported similar voriconazole exposure in children (<12 years) compared to adults with IV doses of 7-
215 9 mg/kg BID (13, 14, 26). This prompted higher dosing regimens in children compared to adults. Although 
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216 voriconazole has been reported to display near-linear pharmacokinetics in children receiving multiple 
217 doses of 3 mg/kg and 4 mg/kg BID IV(15) (i.e. doses that have been found effective in clinical trials 
218 with adults), increasing evidence suggests saturated (non-linear) pharmacokinetic behavior is 
219 observed in children receiving doses higher than 7 mg/kg BID. We found no predictable relationship 
220 between dose and Cmin (Figure 1,2) and it remains unclear from current literature if such a 
221 relationship exists. Given the high maintenance doses in our study (median 23.1 mg/kg/day), this 
222 could explain the absence of a dose/concentration relationship. Another explanation could be found 
223 in the high intra-subject variability in voriconazole Cmin both after IV and PO dosing (figure 1), which is 
224 consistent with other pediatric studies (12-14, 26).
225
226 Due to the retrospective nature of this study, laboratory data on the majority of our patients was 
227 limited and often obtained only on the day of voriconazole TDM. In addition, markers for hepatic 
228 function were not always investigated in parallel. It was therefore not possible to draw any 
229 conclusions on the yet unclear relationship between voriconazole Cmin and hepatotoxicity in pediatric 
230 patients. Because the focus of our study on the relationship between dose adjustments and target 
231 attainment, we did not monitor for voriconazole-related adverse events (e.g. neurological adverse 
232 events, phototoxic skin reactions and potentially proarrhythmic conditions) in relation to dose or 
233 exposure.
234
235 Despite rapid dose adaptations after the first subtherapeutic Cmin in our study (median of 2 days), a 
236 median of 15 days were required to obtain an adequate Cmin, increasing the risk of inadequately 
237 treated fungal infections and unfavourable outcome. Of all dose adaptations following both sub –and 
238 supratherapeutic Cmin, only 45% resulted in a therapeutic Cmin between 1-4 mg/L at the following 
239 concentration measurement. If we would stretch the therapeutic targets to 1-6 mg/L (assuming all 
240 Cmin between 4-6 mg/L were acceptable based on adequate liver function tests), 56% of dose 
241 adaptations would result in target attainment.
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242
243 Dose adaptations were done by experts with expertise in the field of antifungal pharmacology but 
244 without a nomogram. For purposes of personalized dosing, there is an urgent need to implement 
245 advanced pharmacometric models with "clinician-proof" software, that can take into account all 
246 important determinants for treatment response. Nowadays model-informed precision dosing (MIPD) 
247 can be deployed as a technique to forecast dosing in the individual. Programs such as InsightRx, 
248 DoseMe and Best Dose fulfil this need and are being tested in the clinic. To take advantage of this 
249 approach, solid pharmacokinetic models must be available to be used in MIPD. Here we can still gain 
250 knowledge for this specific drug and the current population as the unexplained inter-individual 
251 variability in published models remains very large. Before implementation in routine patient 
252 management these models must be prospectively validated to demonstrate its value. In addition the 
253 software must comply to relevant legislation (for instance CE label in Europe) when deployed outside 
254 of a research scope. Nevertheless this is the way forward taking advantage of a platform for 
255 individualized treatment with visual feedback. 
256
257 Given the difficulty of target attainment despite dose adaptations, together with the prior observed 
258 relationship between voriconazole exposure and efficacy and adverse events and the large inter -and 
259 intrapatient variability in children, this study underscores the indispensable need for voriconazole 
260 TDM in severely immunocompromised pediatric patients early i  the course of treatment with 
261 multiple follow-up samples during therapy when aiming to optimize treatment outcomes.
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263 Table 1. Baseline characteristics (n=21).
264
Demographics
Gender
Male (n [%]) 8 (38.1)
Female (n [%]) 13 (61.9)
Median age at first VCZa dose (yrs [range]) 7.0 (1.2 – 18.5)
Age class (yrs)
0 – <2 (n [%]) 3 (14.3)
2 – <12 (n [%]) 11 (52.4)
12 – 18 (n [%]) 7 (33.3)
Race
Caucasian (n [%]) 18 (85.7)
Negroid (n [%]) 2 (9.5)
Asian (n [%]) 1 (4.8)
Median weight (kg [range]) 21.9 (9.5 – 65)
Median BMI (kg/m2 [range]) 17.7 (14 – 25.4)
Voriconazole therapy
Median days of VCZa therapy (n [range]) 118 (17-866)
Intravenous administrations (%) 12.5
Oral administrations (%) 87.5
Median total daily dose (mg [range]) 400 (120-2400)
Median total daily dose per kg (mg/kg [range]) 23.1 (6.1 – 109.6)
Patients on temporarily TIDb dosing (n [%]) 4 (19)
Median days of TIDb dosing (n range)
Median total daily dose during TID dosing (mg/kg [range])
60 (6 – 397)
34.4 (13.6 – 109.6)
TID dosing administrations (% of total) 11.1
Therapeutic drug monitoring
Median days until first measurement of VCZa Cminc (n [range]) 3 (0 – 27)
Median plasma concentration of first Cminc (mg/L [IQRd]) 3.1 (1.34 – 7.0)
Initial Cmin adequate (% of all patients)e 11 (52.4)
Intravenous administration (%) 7 (63.6)
Oral administration (%) 4 (36.4)
Initial Cmin below therapeutic range (% of all patients) 4 (19)
Intravenous administration (%) 3 (75)
Oral administration (%) 1 (25)
Initial Cmin above therapeutic range (% of all patients) 6 (28.6)
Intravenous administration (%) 4 (66.7)
Oral administration (%) 2 (33.3)
Total Cmin 485
<1 mg/L (n [%]) 117 (24.1)
1 – 4 mg/L (n [%]) 237 (48.9)
4 – 6 mg/L (n [%]) 45 (9.3)
>6 mg/L (n [%]) 86 (17.7)
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Median concentration of all Cmin (mg/L; range) 2.16 (0 – 28.0)
Dose adaptations
Dose adaptations (n [%]) 243 (50.1)
Dose increases (total)
Dose increase at Cmin <1 mg/L (n [%])
Resulted in increase in Cmin
Resulted in Cmin 1 – 4 mg/L
108
55 (47)
42 (76.4)
33 (60)
Dose decrease (total)
Dose decrease at Cmin >6 mg/L
Resulted in decrease in Cmin
135
45 (33.3)
36 (80.0)
Resulted in Cmin <6 mg/L 23 (51.1)
Resulted in Cmin 1 – 4 mg/L 12 (26.7)
265
266 aVCZ = voriconazole, bTID = three times per day, c Cmin = trough concentration, dIQR = Interquartile range,  eAdequate 
267 therapeutic range of voriconazole Cmin is considered to be between 1 and 4 mg/L (1-6 if adequate liver function tests). 
268 Subtherapeutic Cmin at <1 mg/L, supratherapeutic Cmin at >6 mg/L.
Page 37 of 42
http://mc.manuscriptcentral.com/tmmy
Medical Mycology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
270 Figure 1. Overview of all voriconazole trough concentrations at varying doses (n=485) in 21 patients
271
272
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274 Figure 2. Voriconazole Cmin distribution (%) per formulation per age group
275
276 Cmin: trough concentration. IV: intravenous. PO: Oral.
277
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